These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35887866)

  • 1. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease.
    Baffa ME; Corrà A; Maglie R; Mariotti EB; Montefusco F; Pipitò C; Senatore S; Quintarelli L; Caproni M; Antiga E
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
    Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
    Front Immunol; 2022; 13():915205. PubMed ID: 35844526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
    Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
    Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
    Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
    Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of rituximab in patients with mucous membrane pemphigoid.
    Amir Dastmalchi D; Moslemkhani S; Bayat M; Balighi K; Abedini R; Mahmoudi H; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):1084-1090. PubMed ID: 32723108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
    Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
    Front Immunol; 2022; 13():874108. PubMed ID: 35514989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab preserves vision in ocular mucous membrane pemphigoid.
    Rübsam A; Stefaniak R; Worm M; Pleyer U
    Expert Opin Biol Ther; 2015 Jul; 15(7):927-33. PubMed ID: 25966960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab.
    Baniel A; Oestreicher-Kedem Y; Peled A; Bar-Ilan E; Geller S; Sprecher E; Baum S
    Clin Exp Dermatol; 2021 Jul; 46(5):915-919. PubMed ID: 33811681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
    Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab therapy of recalcitrant bullous dermatoses.
    Wollina U; Koch A; Hansel G
    J Dermatol Case Rep; 2008 Mar; 2(1):4-7. PubMed ID: 21886702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).
    Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R
    J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
    Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
    J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
    Shetty S; Ahmed AR
    J Am Acad Dermatol; 2013 Mar; 68(3):499-506. PubMed ID: 23200198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
    Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
    J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
    Sami N; Ahmed AR
    Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-induced serum sickness in immunobullous disorders: A case series.
    Gheisari M; Safari Giv T; Pourgholi E; Zaresharifi S
    Clin Case Rep; 2024 Jul; 12(7):e9152. PubMed ID: 38979086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.